Ratings Jafron Biomedical Co.,Ltd.

Equities

300529

CNE100002995

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
29.3 ^CNY	-0.10%		+6.39%	+31.80%

Apr. 26	Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023	CI
Apr. 25	Jafron Biomedical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Summary

The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

The company benefits from high valuations in earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
JAFRON BIOMEDICAL CO.,LTD.	+31.80%	3.14B	D+
ABBOTT LABORATORIES	-4.84%	182B	C+
MEDTRONIC PLC	+0.56%	110B	C
BECTON, DICKINSON AND COMPANY	-3.35%	68.11B	A
DEXCOM, INC.	+2.39%	50.53B	B-
CENCORA, INC.	+9.36%	44.8B	B-
HOYA CORPORATION	+2.70%	40.7B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+3.43%	26.53B	A-
TERUMO CORPORATION	+13.67%	25.02B	A-
ZIMMER BIOMET HOLDINGS, INC.	-0.32%	24.96B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes